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Antigen-antibody precipitates can be dissolved by the complement cascade (1). The 
complement-mediated solubilization of immune precipitates requires activation of C3 
via the alternative pathway (2) but not participation of the late-acting components, 
C5 through C9 (1, 3). The classical pathway alone, in the absence of the alternative 
pathway, is not sufficient to solubilize immune complexes (3). 
It has recently been demonstrated that the alternative pathway can be assembled 
from six isolated plasma proteins: C3, factors B and  D, properdin, C3b inactivator 
(C3bINA), x and fllH  (4,  5).  Cells such as rabbit  erythrocytes (6), human  lympho- 
blastoid  (Raji)  cells (7), and Escherichia  coli  (8)  have been shown to be lysed by the 
isolated alternative pathway proteins and membrane attack pathway proteins. The 
question therefore arose as to whether the composite mixture of the isolated alternative 
pathway proteins is capable of solubilizing immune precipitates. In this communica- 
tion we report that, indeed, the six isolated alternative pathway proteins can solubilize 
immune precipitates. In addition, we report on the role of the three regulatory factors 
(C3bINA, fllH, and properdin) in the solubilization process. 
Materials and Methods 
Buffers.  PB:  isotonic  phosphate-buffered  saline,  pH  7.4;  Mg-GPB:  PB  containing  0.1% 
gelatin  and  1.2  mM  MgC12;  EDTA-GPB:  PB  containing  0.1%  gelatin  and  l0  mM  EDTA; 
DGVB: isotonic veronal buffered saline, pH 7.4, containing 0.1% gelatin, 0.15 mM CaCI2, 0.5 
mM MgCI2, and 2.5% dextrose. 
Immune Precipitates. Egg albumin (grade V) was purchased from Sigma Chemical Company, 
St. Louis, Mo. Rabbit antiserum to egg albumin was prepared by injecting a rabbit with egg 
albumin  incorporated in  complete Freund's  adjuvant.  IgG  antibody to egg albumin  was 
isolated  by  DEAE-cellulose  column  chromatograph  y25and by  affinity chromatography on 
Sepharose 4B-egg albumin. The IgG was labeled with  I by the chloramin T method (9). The 
specific activity was 5.5 ×  106 cpm/p.g protein. 
Immune  complexes  were  prepared  at  equivalence with  egg  albumin  and  labeled  IgG 
antibody to egg  albumin.  The mixture was  incubated  at  37°C  for 30  min,  then  at  4°C 
overnight. The resulting precipitates were washed three times by centrifugation in the cold and 
resuspended  in Mg-GPB. 
* Supported, in part, by a grant-in-aid for scientific  research  from the Ministry of Education, Science 
and Culture, the Governmenl of Japan. 
~Abbreviations  used in  this  paper:  Ab,  antibody;  C3bINA,  C3b  inactivator;  DGVB,  isotonic  veronal 
buffered saline,  pH  7.4, containing 0.1% gelatin, 0.15  mM CaCI2, 0.5  mM MgCI2, and  2.5% dextrose; 
EDTA-GPB, PB containing 0.1% gelatin and  10 mM EDTA; Mg-GPB, PB containing 0.1% gelatin and 
1.2  mM  MgCI2;  PB,  isotonic  phosphate-buffered  saline,  pH  7.4; SDS-PAGE, sodium  dodecyl sulfate- 
polyacrylamide gel electrophoresis. 
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Purified Complement Components. Human  C3  (10)  factor B  (11,  12),  factor D  (13),  properdin 
(14), fllH (15), and C3bINA (16) were purified as previously described. The purified properdin 
did not contain detectable amounts of activated properdin, and properdin did not induce C3 
cleavage upon addition to normal serum  (17).  The C3bINA was found  to be contaminated 
with trace amounts of IgG and transferrin, which were eliminated by passage through specific 
immunoabsorbents. 
To  verify purity  of the  components,  10-20 /~g of each  alternative pathway  protein  was 
reduced with 5% 2-mercaptoethanol in 3 M  urea and subjected to 10% sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE)  (18).  Each protein preparation was homolo- 
gous and exhibited the appropriate molecular weight for its polypetide chains. Factors B and 
D, properdin, and fl 1H each demonstrated a single stained band, and (33 and (33blNA, which 
consist of two covalently linked polypeptide chains revealed two bands  (Fig.  1). The protein 
concentrations were calculated from their optimal densities at 280 rim, under the assumption 
that an absorption coefficient value of 1.0 equals 1 mg/ml. 
C3 was trace labeled with  131I by insolubilized lactoperoxidase (Worthington Biochemical 
Corp., Freehold, N.J.)  (19) without loss of functional activity. The specific activity was 6.4 × 
10  ~ cpm/#g protein. 
For titration of C3, guinea pig C1  (20),  human C4  (21),  C2  (22),  and C5  (10),  and guinea 
pig C6, C7, C8, and C9 (20) were partially purified by previously described techniques. 
Preparation of the Isolated Component Mixture.  The alternative complement pathway was recon- 
structed with one-fourth the physiological concentrations of purified C3 (300 #g/ml), factor B 
(50/~g/ml), factor D  (1/~g/ml), properdin (5 p,g/ml), C3bINA (10/~g/ml), and fllH (127.5/tg/ 
ml). The buffer was Mg-GPB. 
Serum Lacking in Classical Pathway Function (EGTA-Serum).  Fresh human serum containing 10 
FIG.  1.  Preparations  of the purified  alternative pathway components  analysed  by SDS-PAGE 
under reducing conditions. The marker proteins were 94,000 phosphorylase B, 68,000 bovine serum 
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mM EGTA and 5 mM MgC12 was used as a reagent, allowing complement activation by the 
alternative pathway alone. 
Solubilization Assays. Solubilization assays were carried out in Mg-GPB as described (1).  In 
kinetic studies, immune precipitates were added to a  mixture of the six alternative pathway 
proteins. Then, aliquots were taken at selected times and immediately mixed with 2 ml of cold 
EDTA-GPB. Supernates and pellets were separated by centrifugation at 5,000 g for 20 min and 
assayed for radioactivity in a gamma counter. 
Binding  of  1~1LC3  to  Immune  Precipitates Incubated with  the  Six  Isolated  Alternative  Pathway 
Components.  Immune precipitates containing  1.75/~g of complexed antibody (Ab) were incu- 
bated at 37°C  in a  total volume of 400/tl, with the six isolated proteins at one-fourth their 
serum concentrations, to which 0.02 #g of ~31I-C3 had been added. 40-#1 aliquots were taken at 
selected times and mixed with 2 ml of EDTA-GPB. Precipitates were separated from supernates 
by centrifugation in the cold at 5,000 g for 20 min and washed three times with cold EDTA- 
GPB. ~2SI-Ab  and a31I-C3 in the supernates and precipitates were counted. The amount of Ab 
and C3 in nonsolubilized precipitates at different times was calculated, and then the number 
of C3 molecules bound to one molecule of IgG Ab was calculated, under the assumption that 
the molecular weights of IgG and the C3 fragment bound to the precipitates were 150,000 and 
180,000,  respectively. 
Molar Ratio of C3/Ab in the Solubulized Complexes. Immune precipitates were incubated with 
the six isolated proteins under the conditions described above. 70-#1 aliquots were taken at 0, 
20, 30, and 60 rain, mixed with 500/~1 of EDTA-GPB, and centrifuged, a25I-Ab in the supernates 
and precipitates was counted. The supernates were reacted at 37°C for 30 rain with anti-rabbit 
IgG (N. L. Cappel Laboratories Inc. Cochranville, Pa.). The resulting immune complexes were 
removed by the addition of Staphylococcus aureus (Pansorbin, Calbiochem-Behring Corp., Amer- 
ican Hoechst Corp., San Diego, Calif.), followed by a 30-min incubation at 0°C with shaking. 
The amounts of antisera and Staphylococcus aureus were determined in preliminary experiments. 
After washing three times with 2 ml of EDTA-GPB, 12~I-Ab  and 131I-C3 bound to the bacteria 
were counted. The amount of C3 specifically bound was then calculated, that is, the amount 
of C3 bound at 20, 30, and 60 rain minus that of C3 at time 0. 
Hemolytic Assay of C3.  EAC 142 were prepared with guinea pig C l, human C4, and oxidized 
human C2 (23). 0.2 ml of dilutions of the test samples in DGVB were mixed with 0.2 ml of 1 
×  10S/ml EAC 142 and 0.2 ml of a reagent containing 200 U  each/ml of C5, C6, C7, C8, and 
C9.  These mixtures were incubated at  37°C  for 60 min, and after the addition of 2.4 ml of 
DGVB, the degree of hemolysis was determined spectrophotometrically at 412  nm. 
Results 
Solubilization  of Immune  Precipitates  by  the  Six  Isolated Alternative  Pathway  Proteins.  A 
reaction mixture was constituted to contain one-fourth the respective serum concen- 
trations of purified C3, factor B, factor D, properdin, C3bINA, and/~ 1H. The mixture 
was  incubated  at  37°C  with  immune  precipitates of egg albumin  and  radiolabeled 
rabbit IgG antibody to egg albumin, and their solubilization was assayed kinetically. 
For comparison, solubilization by a  1:4 dilution of human serum or EGTA-serum was 
examined. As shown in Fig. 2, immune precipitates were solubilized by the six purified 
components. The kinetic curve of solubilization is virtually identical to that obtained 
with  EGTA-serum.  In  human  serum,  solubilization  proceeded  at  a  faster  rate, 
indicating that the classical pathway activation enhances solubilization. No solubili- 
zation was observed when individual proteins, such as C3, factor B, or factor D, were 
deleted from the complete mixture. 
Rote of the Three Regulatory Factors in Solubilization.  In the experiments shown in Table 
I, we evaluated  the participation of C3bINA,/~IH,  and properdin in the process of 
solubilization. The various mixtures described in Table I were incubated at 37°C  for 
1 h  with  immune  precipitates containing 125I-Ab.  Supernates and pellets were sepa- 
rated by centrifugation and assayed for solubilization and residual C3 activity. In the 1746  SOLUBILIZATION  OF  IMMUNE  PRECIPITATES  BY  SIX  PROTEINS 
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FI~.  2.  Kinetics of solubilization  in the six isolated alternative pathway proteins. Immune precip- 
itates  containing 0.44 /~g of Ab  were  incubated at  37°C  with  200  /.tl of a  mixture of the six 
components (0) at one-fourth their serum levels or with 200 #l of a  I:4 dilution of human serum 
(m) or of EGTA-serum (A). 25-btl aliquots were taken from the mixture at selected  times, diluted 
with 2 ml of  cold EDTA-GPB, and centrifuged. Supernates and pellets were assayed for radioactivity. 
When the purified components or the 1:4 dilution of human serum were treated with EDTA, no 
solubilization  was observed. 0, EDTA-serum; O, EDTA-components. 
TABLE  I 
C3 Consumption and Solubilization in  Various Mixtures of the Six 
Isolated Components 
C3 consumption* 
Protein mixtures:~  With antigen-  Without antigen-  Solubilization 
antibody§  antibody 
%  %  % 
C3 B D P C3bINA/~IH  47.9  0  60.9 
C3 B D C3bINA/~IH  4.6  0  12.1 
C3 B D P C3bINA  99.2  99.0  13.5 
C3 B D P/~IH  38.5  39.0  10.8 
C3 B D P  99.2  99.2  9.8 
C3 B D  98.7  99.2  10.2 
Buffer  --  --  9.6 
* The residual  C3 was assayed  by hemolytic titration. Another control consisted  of 
antigen or antibody alone incubated with the mixtures.  The results were the same 
as those obtained without antigen-antibody. 
:~ The protein concentrations were C3, 300 #g/ml; factor B, 50/~g/ml;  factor D, 1 #g/ 
ml;  properdin, 5 /tg/ml; C3bINA,  10 p.g/ml;  /~IH,  127.5 /~g/ml. The buffer was 
Mg-GPB, and the total volume of the reaction mixtures was 200/11. 
§ Immune complexes  (antigen-antibody) contained 0.44 p.g Ab. 
absence  of  immune  precipitates,  the  mixture  containing  all  the  six  components 
exhibited no loss of hemolytic C3  activity, even after prolonged incubation at  37°C. 
The  addition  of  immune  precipitates  to  the  complete  mixture  resulted  in  60% 
solubilization  of  the  precipitates  and  47.9%  consumption  of  C3,  indicating  that 
immune complexes containing rabbit IgG Ab are activators of the alternative pathway 
and  that  as  a  result  of the  activation,  solubilization takes  place.  In  the  properdin- 
deficient reaction mixture, neither solubilization nor C3  consumption  was observed. TEIZO  FUJITA, YUKO TAKATA, AND NOBORU  TAMURA  1747 
On  the  other  hand,  the  absence  of/~IH  allowed  total  consumption  of C3  in  the 
absence of immune precipitates, and no effect on  the immune precipitates could be 
recognized. When C3bINA was deleted from the reaction mixture, solubilization did 
not occur. The same degree of C3 inactivation was observed in both the presence and 
the absence of immune  precipitates. These  results indicated that  in  the absence of 
either,B1H or C3bINA, cleavage of C3 occurs only in the fluid phase. Therefore, the 
presence of a  regulated fluid-phase reaction is essential for solubilization. This is more 
clearly shown in the following experiments. 
Decreasing amounts of C3bINA and +81H were added to a constant amount of C3, 
factor B, factor D, and properdin. The mixtures were incubated at 37°C  for  1 h  with 
immune precipitates. As shown in Fig. 3, C3 consumption increased in a  dose-related 
manner with decreasing inputs of C3bINA and/J1H. The degree of solubilization was 
proportional to the amounts of C3bINA and/~IH  in the mixture, and the maximum 
solubilization was  observed  in  a  reaction  mixture  of the  six  purified  components 
reconstituted to their relative serum concentrations. 
In short, it is likely that C3bINA and/~IH  function as regulators that retard fluid- 
phase amplification of C3 cleavage so that the reaction can be directed to the immune 
precipitates. 
Incorporation of C3  into  the  Immune  Precipitates.  The  experiments  described  above 
suggested  that  solubilization  results  from  efficient  fixation  of C3  on  the  immune 
precipitates. In subsequent  experiments, we studied the kinetics of C3 incorporation 
into the immune aggregates incubated with the isolated component mixture. Immune 
precipitates containing t2SI-labeled Ab were incubated at 37°C  with the six purified 
proteins containing lmI-labeled C3. Fig. 4 shows clearly that C3 bound rapidly to the 
aggregates. The onset of solubilization followed the binding of one molecule of C3 to 
one molecule of Ab in the precipitates. After 15 min,  1.4 molecules of C3 were bound 
to one molecule of Ab, and at that  time solubilization had only started. At 30 rain, 
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Ft~.  3+  Role of C3blNA and fllH in solubilization. Various amounts of C3bINA (3.3-0.2/~g/ml) 
and ~IH (42.5-2.7 #g/ml) were added to mixtures of C3 (400 #g/ml), factor B (67 #g/ml), factor 
D (1.3/~g/ml), and properdin (6.7/tg/ml) constituted  to contain  one-third serum concentrations. 
The mixtures were incubated in a total volume of 200 ILl at 37°C for 1 h with immune precipitate 
containing 0.38 #g of Ab. Supernates and pellets were separated by centrifugation  and assayed for 
solubilizatlon (  ) and C3 consumption  (- - -). When the ratio of C3bINA and/31H to the other 
components was equal to their physiological concentration  in serum, the relative concentrations of 
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FIG. 4.  Incorporation  of C3 into the immune  precipitates. Immune precipitates containing 1.75 
Fg of Ab were incubated in a total volume of 400 ~l with the six isolated component mixture (O) or 
a mixture (11) of C3, factor  laL,  h  en  e  B, factor D, and properdin, to which 0.02 ~tg of  I-C3  ad be  add d. 
The control (&) contained *alI-C3  and Mg-GPB. 40-bd aliquots were taken at the indicated times, 
mixed with 2 ml of EDTA-GPB, and centrifuged. Precipitates were washed three times with cold 
buffer. 12SI-Ab  and 1s1I-C3 in the supernates and pellets were counted. The number of C3 molecules 
bound to one molecule of Ab in the precipitates was calculated. 
2.2 molecules of C3 were bound and solubilization exceeded 50%.  In contrast, more 
than one molecule of C3 was never bound  to one molecule of Ab in the mixture of 
C3, factor B, factor D, and properdin, and no solubilization was observed. 
Finally, we  determined  the  C3:Ab  ratio  in  the  solubilized  complexes.  Immune 
precipitates were  incubated  with  the six purified components under  the conditions 
described in the legend of Fig. 4.  The solubilized complexes at  20,  30,  and  60  rain 
were  immunoprecipitated  with  specific  antisera  to  rabbit  IgG.  Precipitates  were 
assayed for zzsI and zatI. 90% or moreZ25I-Ab were precipitated. The molar ratio of C3: 
Ab was 0.99,  1.08, and 0.86 at 20, 30, and 60 rain, respectively. These values represent 
means of duplicate determinations. 
Discussion 
This is the first reported demonstration of the solubilization of immune precipitates 
entirely by  isolated alternative pathway  proteins.  That  the  alternative pathway  of 
complement activation can be assembled from C3,  factors B  and  D, properdin, and 
the three known  regulatory factors has been documented  (4, 5).  Previous studies  (1, 
3, 24)  have demonstrated that  complement-mediated solubilization of immune  pre- 
cipitates proceeds via the alternative activation pathway alone, but this is enhanced 
by  concomitant  participation  of the  classical activation  pathway.  The  late-acting 
complement  components  are  thought  to  be  nonessential  for  solubilization  (1,  3). 
However,  whether  solubilization  is  mediated  solely  by  the  alternative  activation 
pathway has heretofore not been critically evaluated. The results of this study indicate 
that  no factors other than  the six isolated alternative pathway proteins are essential 
for  complement-mediated  solubilization. The  quantitative  similarity of the  kinetic TEIZO  FUJITA, YUKO TAKATA, AND NOBORU TAMURA  1749 
curves obtained with the component mixture and with EGTA-serum further supports 
our conclusion. 
We confirmed the previous observation (25)  that immune complexes activate the 
alternative pathway. In addition, our findings should serve to clarify the mechanisms 
of activation of the alternative pathway by immune complexes. As shown in Table I, 
no  loss  of hemolytic  C3  activity  was  observed  in  a  mixture  of the  six  purified 
components. The introduction of immune complexes to the mixture induced moderate 
C3  consumption  and  efficient C3  fixation to  the  complexes  (Table I  and  Fig.  4). 
When C3bINA and/~ 1H were deleted from the mixture, complete consumption of C3 
occurred in the fluid phase and resulted in a very small amount of C3 fixation. These 
results  agree  well  with  the  concept  that  an  activator of the  alternative  pathway 
provides sites  that  protect  bound  C3b  from  the  action  of C3bINA  and  ~IH  and 
permits C3b deposited by the low-grade fluid-phase reaction to assemble a membrane° 
associated  amplification convertase that  can  deposit  additional  protected C3b  (4). 
Therefore,  it  is  clear  that  immune  complexes  have  protected  C3b  sites,  thereby 
activating the alternative pathway. 
Another important  finding is that  solubilization  followed the binding of at  least 
one molecule of C3 to one molecule of Ab in the precipitates (Fig. 4). The molar ratio 
of C3:Ab in the solubilized complexes is ~ 1. The precise mechanism of solubilization 
is not entirely clear. However, our findings strongly support the concept (2, 25, 26) 
that C3  fragments intercalate into the antigen-antibody lattice and disrupt  it suffi- 
ciently to generate small,  soluble immune complexes. Therefore, it is  important  to 
clarify the nature of binding C3 fragments to the immune complexes. Hydrophobic 
interaction and covalent, esterlike linkage may be involved in this binding (27). This 
is currently under investigation. 
Summary 
Immune precipitates were solubilized by the alternative pathway of complement 
assembled from isolated proteins, i.e., C3, factor B, factor D, properdin, C3b inacti- 
vator (C3bINA), and/31H. The kinetic curves of solubilization in the isolated system 
and in EGTA-serum were virtually indistinguishable. No requirement of other factors 
was apparent. 
Deletion of C3bINA and ,81H from the complete mixture caused total consumption 
of C3  in  the fluid phase and  resulted in  neither C3  binding  to the complexes nor 
solubilization. Thus, the presence of a  regulated fluid-phase reaction is essential for 
efficient fixation of C3 and the consequent solubilization. In addition, properdin plays 
an essential  role in complement-mediated solubilization in  the presence of the two 
regulators. 
A large amount of C3 was incorporated into the antigen-antibody lattice. Sotubi- 
lization of immune complexes started after the binding of one C3  molecule to one 
antibody  molecule  in  the  complexes,  and  the  molar  ratio  of C3:antibody  in  the 
solubilized complexes also is ~ 1. 
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